Dwight Owen1, Benjamin Chu2, Amy M Lehman3, Lakshmanan Annamalai4, Jennifer H Yearley4, Konstantin Shilo5, Gregory A Otterson6. 1. Division of Medical Oncology, Department of Internal Medicine, Ohio State University Wexner Medical Center and James Cancer Hospital and Solove Research Institute, Columbus, Ohio. 2. Helen and Gary Gray Cancer Center, Hartford Hospital, and University of Connecticut School of Medicine, Hartford, Connecticut. 3. Center for Biostatistics, Ohio State University, Columbus, Ohio. 4. Merck Research Laboratories, Palo Alto, California. 5. Department of Pathology, Ohio State University Wexner Medical Center and James Cancer Hospital and Solove Research Institute, Columbus, Ohio. 6. Division of Medical Oncology, Department of Internal Medicine, Ohio State University Wexner Medical Center and James Cancer Hospital and Solove Research Institute, Columbus, Ohio. Electronic address: Greg.Otterson@osumc.edu.
Abstract
INTRODUCTION: Thymic epithelial tumors (TETs) including thymoma and thymic carcinoma are rare tumors with little data available to guide treatment. Immunotherapy with checkpoint blockade has shown promising activity, but data regarding the expression patterns and prognostic implications of programmed death 1 (PD-1) and its ligand (PD-L1) in TETs have yielded conflicting results. Intratumoral heterogeneity of PD-1/L1 expression has been shown in other cancers, but has not been described in the TET literature. METHODS: We performed a retrospective single-center review of 35 patients with resected TET. PD-1/L1 expression was assessed by immunohistochemistry using PD-1 clone: NAT105 and PD-L1 clone: 22C3. Tumor samples from 35 patients were evaluated including 32 patients with thymoma and 3 patients with thymic carcinoma. RESULTS: PD-L1 expression was detected in 83% (29 of 35) tumor samples, including 100% (3 of 3) of thymic carcinoma patients and 81% (26 of 32) of thymoma patients. PD-1 expression was detected in 77% (27 of 35), including 33% (1 of 3) of thymic carcinoma patients and 81% (26 of 32) thymoma patients. High PD-1 expression was associated with lower grade tumors. Unlike prior studies, PD-L1 expression was not associated with higher grade tumors or higher stage. Neither PD-L1 nor PD-1 expression was significantly associated with survival. Three patients with thymoma had multiple tumor sections evaluated for expression of PD-1/L1, with differing expression patterns of both PD-L1 and PD-1 observed in two patients. CONCLUSIONS: This study confirms high expression of PD-L1 and PD-1 in TET and shows for the first time intratumoral heterogeneity of PD-L1 and PD-1 in thymoma patients.
INTRODUCTION:Thymic epithelial tumors (TETs) including thymoma and thymic carcinoma are rare tumors with little data available to guide treatment. Immunotherapy with checkpoint blockade has shown promising activity, but data regarding the expression patterns and prognostic implications of programmed death 1 (PD-1) and its ligand (PD-L1) in TETs have yielded conflicting results. Intratumoral heterogeneity of PD-1/L1 expression has been shown in other cancers, but has not been described in the TET literature. METHODS: We performed a retrospective single-center review of 35 patients with resected TET. PD-1/L1 expression was assessed by immunohistochemistry using PD-1 clone: NAT105 and PD-L1 clone: 22C3. Tumor samples from 35 patients were evaluated including 32 patients with thymoma and 3 patients with thymic carcinoma. RESULTS:PD-L1 expression was detected in 83% (29 of 35) tumor samples, including 100% (3 of 3) of thymic carcinomapatients and 81% (26 of 32) of thymomapatients. PD-1 expression was detected in 77% (27 of 35), including 33% (1 of 3) of thymic carcinomapatients and 81% (26 of 32) thymomapatients. High PD-1 expression was associated with lower grade tumors. Unlike prior studies, PD-L1 expression was not associated with higher grade tumors or higher stage. Neither PD-L1 nor PD-1 expression was significantly associated with survival. Three patients with thymoma had multiple tumor sections evaluated for expression of PD-1/L1, with differing expression patterns of both PD-L1 and PD-1 observed in two patients. CONCLUSIONS: This study confirms high expression of PD-L1 and PD-1 in TET and shows for the first time intratumoral heterogeneity of PD-L1 and PD-1 in thymomapatients.
Authors: Wendy A Cooper; Thang Tran; Ricardo E Vilain; Jason Madore; Christina I Selinger; Maija Kohonen-Corish; PoYee Yip; Bing Yu; Sandra A O'Toole; Brian C McCaughan; Jennifer H Yearley; Lisa G Horvath; Steven Kao; Michael Boyer; Richard A Scolyer Journal: Lung Cancer Date: 2015-05-18 Impact factor: 5.705
Authors: Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer Journal: N Engl J Med Date: 2016-10-08 Impact factor: 91.245
Authors: Marcella Callea; Laurence Albiges; Mamta Gupta; Su-Chun Cheng; Elizabeth M Genega; André P Fay; Jiaxi Song; Ingrid Carvo; Rupal S Bhatt; Michael B Atkins; F Stephen Hodi; Toni K Choueiri; David F McDermott; Gordon J Freeman; Sabina Signoretti Journal: Cancer Immunol Res Date: 2015-05-26 Impact factor: 11.151
Authors: Jamaal A Rehman; Gang Han; Daniel E Carvajal-Hausdorf; Brad E Wasserman; Vasiliki Pelekanou; Nikita L Mani; Joseph McLaughlin; Kurt A Schalper; David L Rimm Journal: Mod Pathol Date: 2016-11-11 Impact factor: 7.842
Authors: Joon Seon Song; Deokhoon Kim; Ji Hyun Kwon; Hyeong Ryul Kim; Chang-Min Choi; Se Jin Jang Journal: Front Oncol Date: 2019-10-15 Impact factor: 6.244
Authors: Isabelle Rouquette; Estelle Taranchon-Clermont; Julia Gilhodes; Maria-Virginia Bluthgen; Romain Perallon; Lara Chalabreysse; Anne De Muret; Veronique Hofman; Alexander Marx; Marie Parrens; Veronique Secq; Vincent Thomas de Montpreville; Françoise Galateau-Salle; Pierre Brousset; Julie Milia; Nicolas Girard; Benjamin Besse; Thierry Jo Molina; Julien Mazières Journal: Biomark Res Date: 2019-12-04